{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:24Z","timestamp":1787019084545,"version":"build-2736575974"},"reference-count":18,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Androgen deprivation therapy remains the essential treatment for disseminated prostate cancer. Interstitial pneumonitis following this therapy has been documented for just a few cases. However, reported cases frequently describe the onset of symptoms after recent administration (days or a few weeks) of both GnRH analogues and androgen antagonists, which makes the precise individual impact of each treatment difficult to estimate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>This report presents a case of a 94-year-old patient with interstitial pneumonitis whose onset started three months after the first dose of leuprorelin and bicalutamide for a metastatic prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Once other possible diagnosis were ruled out, empiric corticosteroid treatment was initiated within 48 h of the admission. A spectacular clinical and radiological improvement was observed after 3 doses of steroids, enabling the patient to recover his basal respiratory situation. We considered that the most probable cause was toxic interstitial pneumonitis induced by leuprorelin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To our knowledge, it describes the longest interval between last administration of antiandrogen therapy and the development of pneumonitis. This fact may support a direct relation with leuprorelin, whose serum levels remain high for months because of its long-acting depot formulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221084058","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:23:45Z","timestamp":1646209425000},"page":"1910-1913","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report"],"prefix":"10.1177","volume":"28","author":[{"given":"Paula Luc\u00eda","family":"Villalba-Cuesta","sequence":"first","affiliation":[{"name":"Department of Oncology, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-9095","authenticated-orcid":false,"given":"Carmen","family":"\u00c1lvaro-Vegue","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Girado","family":"Carrasco-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Fundaci\u00f3n Jim\u00e9nez Diaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gomis-Goti","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-6710","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Garc\u00eda-Villa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"bibr1-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds624"},{"key":"bibr2-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"bibr3-10781552221084058","unstructured":"EAU Guidelines. Edn presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4."},{"key":"bibr4-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6506.1387"},{"key":"bibr5-10781552221084058","first-page":"211","volume":"51","author":"Shioi K","year":"2005","journal-title":"Acta Urol Jpn"},{"key":"bibr6-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1378\/chest.93.5.1106"},{"key":"bibr7-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1136\/thx.47.8.622"},{"key":"bibr8-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62106-2"},{"key":"bibr9-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0239-x"},{"key":"bibr10-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63059-3"},{"key":"bibr11-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63270-1"},{"key":"bibr12-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.146"},{"key":"bibr13-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2003.00705.x"},{"key":"bibr14-10781552221084058","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872016001000017"},{"key":"bibr15-10781552221084058","first-page":"239","volume":"20","author":"Naranjo CA","year":"1981","journal-title":"Clin Pharmacol"},{"key":"bibr16-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.02.019"},{"key":"bibr17-10781552221084058","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010"},{"key":"bibr18-10781552221084058","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221084058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221084058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221084058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:45Z","timestamp":1777688805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221084058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10781552221084058"],"URL":"https:\/\/doi.org\/10.1177\/10781552221084058","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}